Phase II trial of doxorubicin and docetaxel plus granulocyte colony- stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196

Journal of Clinical Oncology

Volumn 18, Issue 12, 2000, Pages 2369-2377

  Sparano, Joseph A ^a   O'Neill, Anne ^a   Schaefer, Paul L ^a   Falkson, Carla I ^a   Wood, William C ^a  

^a TOLEDO HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034053684     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.12.2369     Document Type: Article

References (34)

1. Honig SF: Treatment of metastatic disease: Hormonal and chemotherapy, in Harris JR, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Lippincott-Raven, Philadelphia, PA, 1996, pp 669-734
2. A'Hern RPA, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993
3. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352:930-942, 1998
4. Bissery MC, Nohynek G, Sandernink GJ, et al: Docetaxel: A review of preclinical and clinical experience - Part I. Clinical experience. Anti-Cancer Drugs 6:1943-1951, 1995
5. Rowinsky EK, Donehower RC: Drug therapy: Paclitaxel. N Eng J Med 332:1004-1014, 1995
6. Henderson IC, Berry D, Demetri G, et al: Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive breast cancer. Proc Am Soc Clin Oncol 17:101a, 1998 (abstr 390)
7. Sparreboom A, van Tellingen O, Nooijen WJ, et al: Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti-Cancer Drugs 9:1-17, 1998
8. Haldar S, Chintapalli J, Croce C: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56:1253-1255, 1996
9. Belotti D, Vergani V, Drudis T, et al: The microtubule drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849, 1996
10. Verschueren H, Dewit J, DeBraekeller J, et al: Motility and invasive potency of murine T-lymphoma cells: Effect of microtubules inhibitors. Cell Biol Int 128:11-19, 1994
11. Stracke ML, Soroush M, Liotta LA, et al: Cytoskeletal agents inhibit motility and adherence of human tumor cells. Kidney Int 43:151-157, 1993
12. Sledge GW Jr, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin versus paclitaxel versus doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997 (abstr 2)
13. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
14. Dombernowsky P, Gehl J, Boesgaard M, et al: Doxorubicin and paclitaxel: A highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23:23-27, 1996 (suppl 11)
15. Gianni L, Bigano L, Locatelli A, et al: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15:1906-1915, 1997
16. Sparano JA, Hu P, Rao RM, et al: Phase II trial of doxorubicin and paclitaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study (E4195). J Clin Oncol 17:3828-3834, 1999
17. Misset JL, Dieras V, Bozec L, et al: Long-term follow-up of the phase I/II study of docetaxel and doxorubicin as first line chemotherapy of metastatic breast cancer. Proc Am Soc Clin Oncol 17:160a, 1998 (abstr 612)
18. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
19. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332, 1997
20. Swain S: Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Sem Oncol 25:43-47, 1998 (suppl 10)
21. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
22. Physician's Desk Reference (ed 53). Montvale, NJ, Medical Ecomics Company Inc, 1999, pp 2609-2614
23. Nabholtz JM, Falkson G, Campos D, et al: A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 18:127a, 1999 (abstr 485)
24. Nabholtz JM, Mackey JR, Smylie M, et al: Phase II study of Taxotere (docetaxel), doxorubicin, and cyclophosphamide (TAC) in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 16:148a, 1997 (abstr 518)
25. Von Minckwitz G, Costa SD, Eiermann W, et al: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999-2005, 1999
26. Sparano JA: Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Sem Oncol 25:66-71, 1998 (suppl 10)
27. Bellot R, Robert J, Dieras V, et al: Taxotere does not change the pharmacokinetic profile of doxorubicin and doxorabicinol. Proc Am Soc Clin Oncol 17:221a, 1998 (abstr 853)
28. Schuller J, Czejka M, Kletzl H, et al: Doxorubicin and Taxotere: A pharmacokinetic study of the combination in advanced breast cancer. Proc Am Soc Clin Oncol 17:205a, 1998 (abstr 790)
29. Esposito M, Venturini M, Vannozzi MO, et al: Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 17:1132-1140, 1999
30. Robert J, Gianni L: Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17:219-252, 1993
31. Sparano JA, Speyer J, Gradishar WJ, et al: Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J Clin Oncol 17:862-869, 1999
32. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998
33. Burstein JH, Younger J, Bunnell CA, et al: Weekly docetaxel (Taxotere) for metastatic breast cancer: A phase II trial. Proc Am Soc Clin Oncol 18:127a, 1999 (abstr 484)
34. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-her2 antibody) to first line chemotherapy for her2-overexpressing metastatic breast cancer markedly increased anti-cancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377)